Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR066 in r/r DLBCL after CD19 CAR-T
NCT04316624Phase 1Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2019
- Primary completion
- Feb 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of C-CAR066 in diffuse large B-cell lymphoma (DLBCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Incidence of adverse events at 12 weeks. Started Sep 2019; status: completed.
02
Drugs
C-CAR066
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04316624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04316624.